GB202409801D0 - Products for use in the treatment and prevention of allergy and associated lung conditions/diseases - Google Patents
Products for use in the treatment and prevention of allergy and associated lung conditions/diseasesInfo
- Publication number
- GB202409801D0 GB202409801D0 GBGB2409801.4A GB202409801A GB202409801D0 GB 202409801 D0 GB202409801 D0 GB 202409801D0 GB 202409801 A GB202409801 A GB 202409801A GB 202409801 D0 GB202409801 D0 GB 202409801D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- allergy
- diseases
- prevention
- products
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2409801.4A GB202409801D0 (en) | 2024-07-05 | 2024-07-05 | Products for use in the treatment and prevention of allergy and associated lung conditions/diseases |
| PCT/EP2025/069197 WO2026008865A1 (en) | 2024-07-05 | 2025-07-04 | Products for use in the treatment and prevention of allergy and lung conditions/diseases associated with an allergy or with a pathogen-driven immune response |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2409801.4A GB202409801D0 (en) | 2024-07-05 | 2024-07-05 | Products for use in the treatment and prevention of allergy and associated lung conditions/diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202409801D0 true GB202409801D0 (en) | 2024-08-21 |
Family
ID=92301674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2409801.4A Pending GB202409801D0 (en) | 2024-07-05 | 2024-07-05 | Products for use in the treatment and prevention of allergy and associated lung conditions/diseases |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202409801D0 (en) |
| WO (1) | WO2026008865A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2540013C2 (en) | 2008-03-13 | 2015-01-27 | Биотест Аг | Agent for treating disease |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| EP3957364A1 (en) * | 2020-08-20 | 2022-02-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases |
| GB202017681D0 (en) * | 2020-11-09 | 2020-12-23 | T Balance Therapeutics Gmbh | Anti-CD4 antibody or fragment thereof for medical use |
-
2024
- 2024-07-05 GB GBGB2409801.4A patent/GB202409801D0/en active Pending
-
2025
- 2025-07-04 WO PCT/EP2025/069197 patent/WO2026008865A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2026008865A1 (en) | 2026-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289167A (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| IL316464A (en) | Use of hpk1 inhibitor in prevention and/or treatment of human pathogen infection | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| ZA202303863B (en) | New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | |
| IL309317A (en) | Treatment of mtres1 related diseases and disorders | |
| EP4291233A4 (en) | Polypeptides and their use in treatment of disease | |
| GB202409801D0 (en) | Products for use in the treatment and prevention of allergy and associated lung conditions/diseases | |
| IL321373A (en) | Treatment of mst1 related diseases and disorders | |
| PL3937948T3 (en) | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | |
| EP4017496A4 (en) | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases | |
| PT4364731T (en) | Composition for use in the treatment of disrupted nasal mucosa and epithelial barrier | |
| EP4171746A4 (en) | Materials and methods for the prevention and treatment of viral respiratory diseases | |
| EP4355355A4 (en) | Treatment of plin1 related diseases and disorders | |
| GB2610895C (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| GB202202541D0 (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| IL300096A (en) | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same | |
| HK40112895A (en) | Oximes and their use in treatment of gba-related diseases | |
| GB202217453D0 (en) | Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity | |
| GB202208255D0 (en) | Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity | |
| GB202208256D0 (en) | Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity | |
| CA3260002A1 (en) | Compositions comprising amino acids for use in the prevention and/or treatment of intestinal diseases | |
| GB202107297D0 (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| HK40100307A (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| HK40093071A (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| IL321120A (en) | Treatment of mtres1 related diseases and disorders |